[
  {
    "sentence": "These PTMs, including phosphorylation, ubiquitination, sumoylation, citrullination, acetylation, methylation, glycosylation, and palmitoylation (Fig. 1), take place in numerous proteins to regulate their stability, activity, cellular localization, interaction with other macromolecules, and the cellular response to different stimuli [9, 15, 24, 25].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "PTMs have been shown to mediate several cellular pathophysiological processes related to breast cancer [24], such as immune response (Fig. 1A), signal transduction (Fig. 1B), cell proliferation, malignant transformation (Fig. 1C), angiogenesis (Fig. 1D), cell cycle regulation (Fig. 1E), metabolic reprogramming (Fig. 1F), autophagy (Fig. 1G), cell epithelial-mesenchymal transition (EMT) and invasion (Fig. 1H), as well as DNA damage repair (Fig. 1I) and apoptosis (Fig. 1J).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel F",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel H",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel J",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel F",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel H",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel J",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel F",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel H",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel J",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These PTMs, including phosphorylation, ubiquitination, sumoylation, citrullination, acetylation, methylation, glycosylation, and palmitoylation (Fig. 1), take place in numerous proteins to regulate their stability, activity, cellular localization, interaction with other macromolecules, and the cellular response to different stimuli [9, 15, 24, 25].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "PTMs have been shown to mediate several cellular pathophysiological processes related to breast cancer [24], such as immune response (Fig. 1A), signal transduction (Fig. 1B), cell proliferation, malignant transformation (Fig. 1C), angiogenesis (Fig. 1D), cell cycle regulation (Fig. 1E), metabolic reprogramming (Fig. 1F), autophagy (Fig. 1G), cell epithelial-mesenchymal transition (EMT) and invasion (Fig. 1H), as well as DNA damage repair (Fig. 1I) and apoptosis (Fig. 1J).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel F",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel H",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel J",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel F",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel H",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel J",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel E",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel F",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel H",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel J",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The interaction of Twist and BRD4 at the enhancer and promoter of WNT5A promote the expression of WNT5A, which leads to the activation of WNT signal pathway to accelerate EMT and tumorsphere formation in basal-like breast cancer cells (Fig. 2A) [28].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "P300 also catalyzes the acetylation of HSPA5 at K353 to inhibit its degradation mediated by E3 ubiquitin-protein ligase GP78 and promotes breast cancer metastasis (Fig. 2B) [62].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Histone deacetylase 6 (HDAC6) is reported to deacetylase cell microtubule structures, such as α-Tubulin and cortactin, and increase the formation of invadopodia that promotes breast cancer cell migration and invasion (Fig. 2C) [58].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "HDAC6 deacetylases survivin to promote its cytoplasmic localization and enhance tumor cell growth and survival by inactivating caspase protein-induced programmed cell death in the cytoplasm (Fig. 2D) [59].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Oncoprotein mammalian hepatitis B X-interacting protein (HBXIP) inhibits chaperone-mediated autophagy (CMA)-dependent degradation of homeobox B13 (HOXB13) via enhancing acetylation of HOXB13 at K277 by p300, and thus induces tamoxifen (TAM)- resistance via downregulating ERα and upregulating interleukin-6 (IL-6) expressions (Fig. 2E) [65].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Sirtuin 2 (SIRT2) is induced via the NOTCH signaling pathway to deacetylate aldehyde dehydrogenase A1 (ALDH1A1) at K353 leading to the increase of its enzyme activity and the promotion of breast cancer stem cells (CSCs) properties (Fig. 2F) [66].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For any particular protein, KATs and KDACs act as Yin and Yang by exerting opposing reversible actions on the regulation of acetylation (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, survivin can be acetylated by CREB binding protein (CBP) at K129 to promote its nuclear localization and act as a tumor suppressor by inhibiting the transactivation of signal transducer and activator of transcription 3 (STAT3) (Fig. 2D) [67].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Oncoprotein HSPA5 acetylated at K353 by p300 is abrogated by HDAC6, which catalyzes the deacetylation of HSPA5 to accelerate its polyubiquitination at K447 by E3 ubiquitin ligase GP78, and induce ubiquitination-mediated protein degradation (Fig. 2B) [60].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Acetylation of ALDH1A1 at K353 by p300/CBP-associated factor (PCAF) inhibits the CSCs population as well as self-renewal property of breast cancer (Fig. 2F) [66].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The acetylation of microtubule structures, such as α-Tubulin and cortactin, by α-Tubulin N-acetyltransferase 1 (ATAT1) and TIP60 decreases the formation of invadopodia and inhibits breast cancer cell migration and invasion (Fig. 2C) [68].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The interaction of Twist and BRD4 at the enhancer and promoter of WNT5A promote the expression of WNT5A, which leads to the activation of WNT signal pathway to accelerate EMT and tumorsphere formation in basal-like breast cancer cells (Fig. 2A) [28].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "P300 also catalyzes the acetylation of HSPA5 at K353 to inhibit its degradation mediated by E3 ubiquitin-protein ligase GP78 and promotes breast cancer metastasis (Fig. 2B) [62].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Histone deacetylase 6 (HDAC6) is reported to deacetylase cell microtubule structures, such as α-Tubulin and cortactin, and increase the formation of invadopodia that promotes breast cancer cell migration and invasion (Fig. 2C) [58].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "HDAC6 deacetylases survivin to promote its cytoplasmic localization and enhance tumor cell growth and survival by inactivating caspase protein-induced programmed cell death in the cytoplasm (Fig. 2D) [59].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Oncoprotein mammalian hepatitis B X-interacting protein (HBXIP) inhibits chaperone-mediated autophagy (CMA)-dependent degradation of homeobox B13 (HOXB13) via enhancing acetylation of HOXB13 at K277 by p300, and thus induces tamoxifen (TAM)- resistance via downregulating ERα and upregulating interleukin-6 (IL-6) expressions (Fig. 2E) [65].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Sirtuin 2 (SIRT2) is induced via the NOTCH signaling pathway to deacetylate aldehyde dehydrogenase A1 (ALDH1A1) at K353 leading to the increase of its enzyme activity and the promotion of breast cancer stem cells (CSCs) properties (Fig. 2F) [66].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For any particular protein, KATs and KDACs act as Yin and Yang by exerting opposing reversible actions on the regulation of acetylation (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, survivin can be acetylated by CREB binding protein (CBP) at K129 to promote its nuclear localization and act as a tumor suppressor by inhibiting the transactivation of signal transducer and activator of transcription 3 (STAT3) (Fig. 2D) [67].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Oncoprotein HSPA5 acetylated at K353 by p300 is abrogated by HDAC6, which catalyzes the deacetylation of HSPA5 to accelerate its polyubiquitination at K447 by E3 ubiquitin ligase GP78, and induce ubiquitination-mediated protein degradation (Fig. 2B) [60].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Acetylation of ALDH1A1 at K353 by p300/CBP-associated factor (PCAF) inhibits the CSCs population as well as self-renewal property of breast cancer (Fig. 2F) [66].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The acetylation of microtubule structures, such as α-Tubulin and cortactin, by α-Tubulin N-acetyltransferase 1 (ATAT1) and TIP60 decreases the formation of invadopodia and inhibits breast cancer cell migration and invasion (Fig. 2C) [68].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The interaction of Twist and BRD4 at the enhancer and promoter of WNT5A promote the expression of WNT5A, which leads to the activation of WNT signal pathway to accelerate EMT and tumorsphere formation in basal-like breast cancer cells (Fig. 2A) [28].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "P300 also catalyzes the acetylation of HSPA5 at K353 to inhibit its degradation mediated by E3 ubiquitin-protein ligase GP78 and promotes breast cancer metastasis (Fig. 2B) [62].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Histone deacetylase 6 (HDAC6) is reported to deacetylase cell microtubule structures, such as α-Tubulin and cortactin, and increase the formation of invadopodia that promotes breast cancer cell migration and invasion (Fig. 2C) [58].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "HDAC6 deacetylases survivin to promote its cytoplasmic localization and enhance tumor cell growth and survival by inactivating caspase protein-induced programmed cell death in the cytoplasm (Fig. 2D) [59].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Oncoprotein mammalian hepatitis B X-interacting protein (HBXIP) inhibits chaperone-mediated autophagy (CMA)-dependent degradation of homeobox B13 (HOXB13) via enhancing acetylation of HOXB13 at K277 by p300, and thus induces tamoxifen (TAM)- resistance via downregulating ERα and upregulating interleukin-6 (IL-6) expressions (Fig. 2E) [65].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Sirtuin 2 (SIRT2) is induced via the NOTCH signaling pathway to deacetylate aldehyde dehydrogenase A1 (ALDH1A1) at K353 leading to the increase of its enzyme activity and the promotion of breast cancer stem cells (CSCs) properties (Fig. 2F) [66].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The interaction of Twist and BRD4 at the enhancer and promoter of WNT5A promote the expression of WNT5A, which leads to the activation of WNT signal pathway to accelerate EMT and tumorsphere formation in basal-like breast cancer cells (Fig. 2A) [28].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "P300 also catalyzes the acetylation of HSPA5 at K353 to inhibit its degradation mediated by E3 ubiquitin-protein ligase GP78 and promotes breast cancer metastasis (Fig. 2B) [62].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Histone deacetylase 6 (HDAC6) is reported to deacetylase cell microtubule structures, such as α-Tubulin and cortactin, and increase the formation of invadopodia that promotes breast cancer cell migration and invasion (Fig. 2C) [58].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "HDAC6 deacetylases survivin to promote its cytoplasmic localization and enhance tumor cell growth and survival by inactivating caspase protein-induced programmed cell death in the cytoplasm (Fig. 2D) [59].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Oncoprotein mammalian hepatitis B X-interacting protein (HBXIP) inhibits chaperone-mediated autophagy (CMA)-dependent degradation of homeobox B13 (HOXB13) via enhancing acetylation of HOXB13 at K277 by p300, and thus induces tamoxifen (TAM)- resistance via downregulating ERα and upregulating interleukin-6 (IL-6) expressions (Fig. 2E) [65].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Sirtuin 2 (SIRT2) is induced via the NOTCH signaling pathway to deacetylate aldehyde dehydrogenase A1 (ALDH1A1) at K353 leading to the increase of its enzyme activity and the promotion of breast cancer stem cells (CSCs) properties (Fig. 2F) [66].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For any particular protein, KATs and KDACs act as Yin and Yang by exerting opposing reversible actions on the regulation of acetylation (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, survivin can be acetylated by CREB binding protein (CBP) at K129 to promote its nuclear localization and act as a tumor suppressor by inhibiting the transactivation of signal transducer and activator of transcription 3 (STAT3) (Fig. 2D) [67].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Oncoprotein HSPA5 acetylated at K353 by p300 is abrogated by HDAC6, which catalyzes the deacetylation of HSPA5 to accelerate its polyubiquitination at K447 by E3 ubiquitin ligase GP78, and induce ubiquitination-mediated protein degradation (Fig. 2B) [60].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Acetylation of ALDH1A1 at K353 by p300/CBP-associated factor (PCAF) inhibits the CSCs population as well as self-renewal property of breast cancer (Fig. 2F) [66].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The acetylation of microtubule structures, such as α-Tubulin and cortactin, by α-Tubulin N-acetyltransferase 1 (ATAT1) and TIP60 decreases the formation of invadopodia and inhibits breast cancer cell migration and invasion (Fig. 2C) [68].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For any particular protein, KATs and KDACs act as Yin and Yang by exerting opposing reversible actions on the regulation of acetylation (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the contrary, survivin can be acetylated by CREB binding protein (CBP) at K129 to promote its nuclear localization and act as a tumor suppressor by inhibiting the transactivation of signal transducer and activator of transcription 3 (STAT3) (Fig. 2D) [67].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Oncoprotein HSPA5 acetylated at K353 by p300 is abrogated by HDAC6, which catalyzes the deacetylation of HSPA5 to accelerate its polyubiquitination at K447 by E3 ubiquitin ligase GP78, and induce ubiquitination-mediated protein degradation (Fig. 2B) [60].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Acetylation of ALDH1A1 at K353 by p300/CBP-associated factor (PCAF) inhibits the CSCs population as well as self-renewal property of breast cancer (Fig. 2F) [66].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The acetylation of microtubule structures, such as α-Tubulin and cortactin, by α-Tubulin N-acetyltransferase 1 (ATAT1) and TIP60 decreases the formation of invadopodia and inhibits breast cancer cell migration and invasion (Fig. 2C) [68].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The binding of p120 and β-catenin to E-cadherin is crucial for the membrane translocation and stability of E-cadherin, hyper-GlcNAcylation of p120 and β-catenin result in decreased membrane translocation of E-cadherin, thus inducing cancer cell metastasis (Fig. 3A) [82].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The N-glycosylation of HER2 protein at asparagine (Asn) 68/124/187/259/530/571/549 can inhibit its binding with Herceptin and activate mitogen-activated protein kinase (MAPK) and PI3K-Akt signaling pathways to promote breast cancer progression (Fig. 3B).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The glycosylated CD63 and MDR1 can interact with each other and co-localized in the cell membrane and play an essential role in reducing the concentration of anticancer drugs in cancer cells by facilitating the efflux of the anticancer drug out of cells, thus leading to drug resistance and cancer invasiveness (Fig. 3B) [107].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This glycosylation-dependent interaction drives an immune inhibitory program that decreases the production of IFN-γ and increases the expression of IL-10 and TNF, thus decreasing the effector T cell proliferation and increasing effector T cell apoptosis (Fig. 4A, I) [110].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For example, the binding of sialylated N-acetyl-d-lactosamine (LacNAc) to siglec-7 on the NK cells can protect the cancer cells from NK cell cytotoxicity by decreasing the production of IFN-γ and other cytotoxic molecules (Fig. 4A, II) [114].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The binding of mucin 1-sialylated core 1 (MUC1-ST) to siglec-9 on monocytes and macrophages can induce the release of factors such as IL-8, IL-6, macrophage colony-stimulating factor (M-CSF), and plasminogen activator inhibitor-1 (PAI-1), that promote tumor growth and induce macrophages to develop a tumor-associated macrophages (TAM) phenotype (Fig. 4A, III) [115, 116].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Similarly, the cancer cells that overexpress sialyl-Lewis X glycans can bind to the endothelial cells and promote tumor metastasis by this mechanism (Fig. 4A, IV) [117].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Moreover, the antibody–drug conjugate, STM108-ADC, induces potent drug-induced cytotoxic activities and bystander effects to kill TNBC cells both in vivo and in vitro (Fig. 4B) [123].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "DeSUMOylation of protein interacting with never in mitosis A (NIMA)-1 (Pin1) at K6 and K63 by SENP1 promotes its protein activity and interaction with the substrate, thereby inducing malignant cell transformation (Fig. 5A) [143].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Sumoylation of the transcription factor Forkhead Box Protein M1 (FOXM1B) at K463 inhibits the expression of miR200 b/c and p21, thus activating the expression of JNK1 and promoting the proliferation of MCF-7 cells (Fig. 5B) [146].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Further, the sumoylation of TβRI enhances its interaction with Smad2/3 and promotes the phosphorylation of Smad3, consequently activating TGF-β-Smad signaling pathway to promote cancer cell metastasis (Fig. 5C I) [148].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Interestingly, a previous study also demonstrated that SENP5 promotes breast cancer invasion by sustaining the sumoylation of TβRI (Fig. 5C II), whose expression is negatively correlated with the prognosis of breast cancer patients [134].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "SENP2 facilitates TGF-β-Smad4 signaling pathway by desumoylating Smad4 at lys159 to promote EMT and cell migration in TNBC cells and sustain cancer stem cell properties (Fig. 5C III) [149].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For example, the sumoylation of Pin1 at lys6 and lys63 suppressed its ability and oncogenic function (Fig. 5A) [143].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Sumoylation of Smad4 at K159 promotes its interaction with the transcriptional corepressor Daxx to repress the transcriptional activity of Smad4, thereby inhibiting the TGF-β-Smad4 signaling pathway and playing the role of a tumor suppressor in breast cancer (Fig. 5C III) [150].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "SENP2 deSUMOylates FOXM1B at K463 and thus upregulates the expression of miR200 b/c and p21 to reduce the proliferation and migration of MCF-7 breast cancer cells (Fig. 5B) [146].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "DeSUMOylation of protein interacting with never in mitosis A (NIMA)-1 (Pin1) at K6 and K63 by SENP1 promotes its protein activity and interaction with the substrate, thereby inducing malignant cell transformation (Fig. 5A) [143].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Sumoylation of the transcription factor Forkhead Box Protein M1 (FOXM1B) at K463 inhibits the expression of miR200 b/c and p21, thus activating the expression of JNK1 and promoting the proliferation of MCF-7 cells (Fig. 5B) [146].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Further, the sumoylation of TβRI enhances its interaction with Smad2/3 and promotes the phosphorylation of Smad3, consequently activating TGF-β-Smad signaling pathway to promote cancer cell metastasis (Fig. 5C I) [148].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Interestingly, a previous study also demonstrated that SENP5 promotes breast cancer invasion by sustaining the sumoylation of TβRI (Fig. 5C II), whose expression is negatively correlated with the prognosis of breast cancer patients [134].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "SENP2 facilitates TGF-β-Smad4 signaling pathway by desumoylating Smad4 at lys159 to promote EMT and cell migration in TNBC cells and sustain cancer stem cell properties (Fig. 5C III) [149].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For example, the sumoylation of Pin1 at lys6 and lys63 suppressed its ability and oncogenic function (Fig. 5A) [143].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Sumoylation of Smad4 at K159 promotes its interaction with the transcriptional corepressor Daxx to repress the transcriptional activity of Smad4, thereby inhibiting the TGF-β-Smad4 signaling pathway and playing the role of a tumor suppressor in breast cancer (Fig. 5C III) [150].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "SENP2 deSUMOylates FOXM1B at K463 and thus upregulates the expression of miR200 b/c and p21 to reduce the proliferation and migration of MCF-7 breast cancer cells (Fig. 5B) [146].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "DeSUMOylation of protein interacting with never in mitosis A (NIMA)-1 (Pin1) at K6 and K63 by SENP1 promotes its protein activity and interaction with the substrate, thereby inducing malignant cell transformation (Fig. 5A) [143].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Sumoylation of the transcription factor Forkhead Box Protein M1 (FOXM1B) at K463 inhibits the expression of miR200 b/c and p21, thus activating the expression of JNK1 and promoting the proliferation of MCF-7 cells (Fig. 5B) [146].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Further, the sumoylation of TβRI enhances its interaction with Smad2/3 and promotes the phosphorylation of Smad3, consequently activating TGF-β-Smad signaling pathway to promote cancer cell metastasis (Fig. 5C I) [148].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Interestingly, a previous study also demonstrated that SENP5 promotes breast cancer invasion by sustaining the sumoylation of TβRI (Fig. 5C II), whose expression is negatively correlated with the prognosis of breast cancer patients [134].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "SENP2 facilitates TGF-β-Smad4 signaling pathway by desumoylating Smad4 at lys159 to promote EMT and cell migration in TNBC cells and sustain cancer stem cell properties (Fig. 5C III) [149].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "DeSUMOylation of protein interacting with never in mitosis A (NIMA)-1 (Pin1) at K6 and K63 by SENP1 promotes its protein activity and interaction with the substrate, thereby inducing malignant cell transformation (Fig. 5A) [143].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Sumoylation of the transcription factor Forkhead Box Protein M1 (FOXM1B) at K463 inhibits the expression of miR200 b/c and p21, thus activating the expression of JNK1 and promoting the proliferation of MCF-7 cells (Fig. 5B) [146].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Further, the sumoylation of TβRI enhances its interaction with Smad2/3 and promotes the phosphorylation of Smad3, consequently activating TGF-β-Smad signaling pathway to promote cancer cell metastasis (Fig. 5C I) [148].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Interestingly, a previous study also demonstrated that SENP5 promotes breast cancer invasion by sustaining the sumoylation of TβRI (Fig. 5C II), whose expression is negatively correlated with the prognosis of breast cancer patients [134].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "SENP2 facilitates TGF-β-Smad4 signaling pathway by desumoylating Smad4 at lys159 to promote EMT and cell migration in TNBC cells and sustain cancer stem cell properties (Fig. 5C III) [149].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For example, the sumoylation of Pin1 at lys6 and lys63 suppressed its ability and oncogenic function (Fig. 5A) [143].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Sumoylation of Smad4 at K159 promotes its interaction with the transcriptional corepressor Daxx to repress the transcriptional activity of Smad4, thereby inhibiting the TGF-β-Smad4 signaling pathway and playing the role of a tumor suppressor in breast cancer (Fig. 5C III) [150].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "SENP2 deSUMOylates FOXM1B at K463 and thus upregulates the expression of miR200 b/c and p21 to reduce the proliferation and migration of MCF-7 breast cancer cells (Fig. 5B) [146].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For example, the sumoylation of Pin1 at lys6 and lys63 suppressed its ability and oncogenic function (Fig. 5A) [143].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Sumoylation of Smad4 at K159 promotes its interaction with the transcriptional corepressor Daxx to repress the transcriptional activity of Smad4, thereby inhibiting the TGF-β-Smad4 signaling pathway and playing the role of a tumor suppressor in breast cancer (Fig. 5C III) [150].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "SENP2 deSUMOylates FOXM1B at K463 and thus upregulates the expression of miR200 b/c and p21 to reduce the proliferation and migration of MCF-7 breast cancer cells (Fig. 5B) [146].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "PRMT1 catalyzes ERα methylation at R260 within the DNA binding domain during rapid estrogen signaling, leading to the activation of the downstream PI3K-Src-Akt signaling pathway, thus promoting the phosphorylation of Akt at Ser473 and resulting in cancer cell proliferation and antiapoptotic effects (Fig. 5D) [171].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "However, future research is required to analyze whether the methylation of p53 plays a role in breast cancer (Fig. 5E).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Intriguingly, some PRMTs undergo automethylation spontaneously, the automethylation of PRMT7 at R531 in the C-terminal of the protein accelerates the interaction with the transcription factor Yin-Yang 1 (YY1) and is vital for its recruitment to the promoter region of E-cadherin to inhibit transcription, thus promoting EMT and breast cancer cell migration and invasion (Fig. 5F) [19].Protein methylation plays a role in tumor suppression in breast cancer\nThe reversible modifications of protein methylation, i.e. methylation and demethylation, of the specific protein at the same site may have contrary effects.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For example, the demethylation of ERα at R260 by JMJD6 inhibits the activation of the PI3K-Src-Akt signaling pathway, thus inhibiting breast cancer cell proliferation (Fig. 5D) [171].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "PRMT1 catalyzes ERα methylation at R260 within the DNA binding domain during rapid estrogen signaling, leading to the activation of the downstream PI3K-Src-Akt signaling pathway, thus promoting the phosphorylation of Akt at Ser473 and resulting in cancer cell proliferation and antiapoptotic effects (Fig. 5D) [171].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "However, future research is required to analyze whether the methylation of p53 plays a role in breast cancer (Fig. 5E).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Intriguingly, some PRMTs undergo automethylation spontaneously, the automethylation of PRMT7 at R531 in the C-terminal of the protein accelerates the interaction with the transcription factor Yin-Yang 1 (YY1) and is vital for its recruitment to the promoter region of E-cadherin to inhibit transcription, thus promoting EMT and breast cancer cell migration and invasion (Fig. 5F) [19].Protein methylation plays a role in tumor suppression in breast cancer\nThe reversible modifications of protein methylation, i.e. methylation and demethylation, of the specific protein at the same site may have contrary effects.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For example, the demethylation of ERα at R260 by JMJD6 inhibits the activation of the PI3K-Src-Akt signaling pathway, thus inhibiting breast cancer cell proliferation (Fig. 5D) [171].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "PRMT1 catalyzes ERα methylation at R260 within the DNA binding domain during rapid estrogen signaling, leading to the activation of the downstream PI3K-Src-Akt signaling pathway, thus promoting the phosphorylation of Akt at Ser473 and resulting in cancer cell proliferation and antiapoptotic effects (Fig. 5D) [171].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "However, future research is required to analyze whether the methylation of p53 plays a role in breast cancer (Fig. 5E).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Intriguingly, some PRMTs undergo automethylation spontaneously, the automethylation of PRMT7 at R531 in the C-terminal of the protein accelerates the interaction with the transcription factor Yin-Yang 1 (YY1) and is vital for its recruitment to the promoter region of E-cadherin to inhibit transcription, thus promoting EMT and breast cancer cell migration and invasion (Fig. 5F) [19].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "PRMT1 catalyzes ERα methylation at R260 within the DNA binding domain during rapid estrogen signaling, leading to the activation of the downstream PI3K-Src-Akt signaling pathway, thus promoting the phosphorylation of Akt at Ser473 and resulting in cancer cell proliferation and antiapoptotic effects (Fig. 5D) [171].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "However, future research is required to analyze whether the methylation of p53 plays a role in breast cancer (Fig. 5E).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Intriguingly, some PRMTs undergo automethylation spontaneously, the automethylation of PRMT7 at R531 in the C-terminal of the protein accelerates the interaction with the transcription factor Yin-Yang 1 (YY1) and is vital for its recruitment to the promoter region of E-cadherin to inhibit transcription, thus promoting EMT and breast cancer cell migration and invasion (Fig. 5F) [19].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For example, the demethylation of ERα at R260 by JMJD6 inhibits the activation of the PI3K-Src-Akt signaling pathway, thus inhibiting breast cancer cell proliferation (Fig. 5D) [171].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For example, the demethylation of ERα at R260 by JMJD6 inhibits the activation of the PI3K-Src-Akt signaling pathway, thus inhibiting breast cancer cell proliferation (Fig. 5D) [171].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "RNF31 acts as an oncogene by catalyzing the monoubiquitination of ERα to increase its stability and promotes the transcription of the ERα signal downstream oncogenic proteins (cyclin D1 and c-myc) to accelerate cell cycle transition and cancer cell proliferation (Fig. 6A) [196].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Moreover, RNF31 inhibits the ubiquitination of MDM2 through an unknown mechanism to accelerate p53 degradation, which resulting in chemotherapy resistance by inhibiting p53 induced cell apoptosis (Fig. 6B) [196, 198].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In addition, RNF31 and RBCK1 are the vital components of linear ubiquitin assembly complex (LUBAC), that mediate the linear polyubiquitination of the inhibitor of κB Kinase (IKK) γ (NEMO), thereby activating the IKK complex and facilitating NF-κB signaling (Fig. 6C) [196].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RBCK1 also increases the transcription of ERα and cyclin B1 by recruitment to the ERα promoter to enhance cancer cell proliferation (Fig. 6D) [199].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RNF31 acts as an oncogene by catalyzing the monoubiquitination of ERα to increase its stability and promotes the transcription of the ERα signal downstream oncogenic proteins (cyclin D1 and c-myc) to accelerate cell cycle transition and cancer cell proliferation (Fig. 6A) [196].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Moreover, RNF31 inhibits the ubiquitination of MDM2 through an unknown mechanism to accelerate p53 degradation, which resulting in chemotherapy resistance by inhibiting p53 induced cell apoptosis (Fig. 6B) [196, 198].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In addition, RNF31 and RBCK1 are the vital components of linear ubiquitin assembly complex (LUBAC), that mediate the linear polyubiquitination of the inhibitor of κB Kinase (IKK) γ (NEMO), thereby activating the IKK complex and facilitating NF-κB signaling (Fig. 6C) [196].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "RBCK1 also increases the transcription of ERα and cyclin B1 by recruitment to the ERα promoter to enhance cancer cell proliferation (Fig. 6D) [199].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Methylation of ERα at K266 by SMYD2 inhibits its acetylation at K266/268 catalyzed by p300, which can be reversed by demethylase LSD1 and promotes the expression of ERα target genes (Fig. 7A) [177].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "HDAC6 catalyzes the deacetylation of HSPA5 at K353 and accelerates its polyubiquitination at K447, thus inducing ubiquitination-mediated protein degradation (Fig. 2B) [60].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, there are many crosstalk between phosphorylation and other PTMs in breast cancer, for example, the crosstalk between methylation and phosphorylation; methylated ERα at R260 by PRMT1 triggers the PI3K-Akt signaling pathway to stimulate the downstream target proteins to undergo phosphorylation modification and resulting in breast cancer cell proliferation and antiapoptotic effects (Fig. 5D) [171].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In addition, there is much crosstalk between O-GlcNAcylation and phosphorylation; for example, T58 of the transcription factor c-Myc can be both a target for phosphorylation and O-GlcNAcylation, while serum starvation promotes O-GlcNAcylation of c-Myc, serum stimulation shows the opposite effects (Fig. 7B) [226].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "The O-GlcNAcylation of p53 at Ser149 inhibits its phosphorylation at Thr155, resulting in a reduced interaction between MDM2 and p53, and consequently inhibits the ubiquitin-dependent degradation of p53 (Fig. 7C) [227].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Similarly, the O-GlcNAcylation of snail1 inhibits its phosphorylation-mediated proteasome degradation (Fig. 3A) [228].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Except for O-GlcNAcylation, the N-glycosylation of PD-L1 can maintain its protein stability by antagonizing the binding of GSK3β and phosphorylation-induced proteasome degradation (Fig. 4B) [122, 123].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For instance, the O-GlcNAcylation of TGF-β activated kinase 1 binding proteins (TABs) at Ser408 is accelerated by its phosphorylation at Thr404, and the O-GlcNAcylated TABs, in turn, activate TGF-β activated kinase 1 (TAK1) and its downstream NF-κB signaling pathway; this positive feedback facilitates the migration and invasion of TNBC (Fig. 7D) [229].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel D",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel D",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel D",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Methylation of ERα at K266 by SMYD2 inhibits its acetylation at K266/268 catalyzed by p300, which can be reversed by demethylase LSD1 and promotes the expression of ERα target genes (Fig. 7A) [177].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "HDAC6 catalyzes the deacetylation of HSPA5 at K353 and accelerates its polyubiquitination at K447, thus inducing ubiquitination-mediated protein degradation (Fig. 2B) [60].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, there are many crosstalk between phosphorylation and other PTMs in breast cancer, for example, the crosstalk between methylation and phosphorylation; methylated ERα at R260 by PRMT1 triggers the PI3K-Akt signaling pathway to stimulate the downstream target proteins to undergo phosphorylation modification and resulting in breast cancer cell proliferation and antiapoptotic effects (Fig. 5D) [171].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel D",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In addition, there is much crosstalk between O-GlcNAcylation and phosphorylation; for example, T58 of the transcription factor c-Myc can be both a target for phosphorylation and O-GlcNAcylation, while serum starvation promotes O-GlcNAcylation of c-Myc, serum stimulation shows the opposite effects (Fig. 7B) [226].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "The O-GlcNAcylation of p53 at Ser149 inhibits its phosphorylation at Thr155, resulting in a reduced interaction between MDM2 and p53, and consequently inhibits the ubiquitin-dependent degradation of p53 (Fig. 7C) [227].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Similarly, the O-GlcNAcylation of snail1 inhibits its phosphorylation-mediated proteasome degradation (Fig. 3A) [228].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Except for O-GlcNAcylation, the N-glycosylation of PD-L1 can maintain its protein stability by antagonizing the binding of GSK3β and phosphorylation-induced proteasome degradation (Fig. 4B) [122, 123].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "For instance, the O-GlcNAcylation of TGF-β activated kinase 1 binding proteins (TABs) at Ser408 is accelerated by its phosphorylation at Thr404, and the O-GlcNAcylated TABs, in turn, activate TGF-β activated kinase 1 (TAK1) and its downstream NF-κB signaling pathway; this positive feedback facilitates the migration and invasion of TNBC (Fig. 7D) [229].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel D",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel D",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel D",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "The STM108 antibody can specifically recognize the Asn192 and Asn200 glycosylation sites of PD-L1 and the antibody–drug conjugate, STM108-ADC, induces potent drug-induced cytotoxic activities and bystander effects to kill TNBC cells both in vivo and in vitro (Fig. 4B) [123].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The STM108 antibody can specifically recognize the Asn192 and Asn200 glycosylation sites of PD-L1 and the antibody–drug conjugate, STM108-ADC, induces potent drug-induced cytotoxic activities and bystander effects to kill TNBC cells both in vivo and in vitro (Fig. 4B) [123].",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  }
]